Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks tra…

Rheological characterization of polycaprolactam anionically synthesized in the presence of lithium chloride

Melt viscosity and dynamic-mechanical data are reported for samples obtained by anionic polymerization of caprolactam, in the presence of LiCl. The full body of results is essentially in line with those previously reported relative to mixtures of inorganic salts and commercial nylon 6, In particular a drastic-decrease of the melting point and of the rate of crystallization is confirmed as well as an increase of the glass transition temperature and of the melt viscosity. Some quantitative differences exist, which may be attributed to the different molecular weight distribution in the polymers employed in the present work.

Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer